QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN’s leadership in genetic interpretation for clinical genomics applications. The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date.
Read the full article: QIAGEN Enhances Leading Clinical Genomics Portfolio with Acquisition of Genoox AI-Powered Software //
Source: https://www.businesswire.com/news/home/20250512358698/en/QIAGEN-enhances-leading-clinical-genomics-portfolio-with-acquisition-of-Genoox-AI-powered-software